Heart failure & cardiomyopathies
Efficacy and Safety of Vutrisiran in Transthyretin Amyloid Cardiomyopathy Across the Age Spectrum: The HELIOS-B Trial
Authors' conclusion
Vutrisiran reduced all-cause mortality and cardiovascular events and maintained function and quality of life in patients with ATTR-CM across the age spectrum, including those ≥80 years.
Study context
- Population
- Patients aged 18–85 years with transthyretin amyloid cardiomyopathy (ATTR-CM), by age category (<75, 75 to <80, ≥80 years)mean age 75.3 ± 6.7
- Participants
- 654 patients
- Comparison
- Vutrisiran vs placebo, by age
Methodological detailsprespecified subgroup analysis by age
- Prespecified subgroup analysis by age
Primary result
As reported in the abstract
Primary composite by age
- Vutrisiran reduced risk of primary composite in all age categories (<75: n=257; 75 to <80: n=201; ≥80: n=196)
- pinteraction = 0.56
- Reduction across age as a continuous function
- pinteraction = 0.50
Further findings
Individual components of primary outcome, by age
- Consistent benefits, no significant treatment-by-age interaction
Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS) and 6MWT, by age
- Functional capacity and quality of life preserved across age groups; KCCQ-OSS
- P for interaction = 0.35
- 6MWT
- = 1.00
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Efficacy and Safety of Vutrisiran in Transthyretin Amyloid Cardiomyopathy Across the Age Spectrum: The HELIOS-B Trial. Eur J Heart Fail. Published 29 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →